Clinical Study to Investigate Use of Exosomal Biomarker to Detect & Monitor Brain Injury in NFL Football Players

On January 25, 2017, researchers with Exosome Sciences, Inc., a diagnostic subsidiary of Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company, today announced plans to initiate a clinical study involving retired National Football League (NFL) players and a data-supported biomarker candidate to detect and monitor Chronic Traumatic Encephalopathy (CTE) in living individuals. CTE is a neurodegenerative disease that has often been found in American football players, boxers, and other individuals with a history of repetitive head trauma. At present, CTE diagnosis is determined after death through an analysis of brain tissue. Planned for initiation in the second quarter, the study intends to establish a clinical collaboration with up to 200 former professional football players and clinical investigators at multiple U.S. locations. If fully enrolled, the study would be the largest to date in former NFL players, who are at a high risk of suffering from CTE. The goal of the study will be to further validate a CTE biomarker candidate known as plasma exosomal tau, or a TauSome™. The biomarker was previously studied as part of the first NIH-funded CTE research program (The DETECT Study), which was managed by the Boston University (BU) CTE Center. Kendall Van Keuren-Jensen, Ph.D., Co-Director of the Translational Genomics Research Institute's (TGen) Center for Noninvasive Diagnostics in Phoenix, will serve as principal investigator for the planned study. Dr. Van Keuren-Jensen is neurodegenerative disease thought leader whose research includes discovery and detection of biomarkers for central nervous system disorders.
Login Or Register To Read Full Story